Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

AYA Cancer Awareness month offers an opportunity for nurses to go further in supporting AYAs with cancer.

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

The MindCap mobile app is likely feasible as an assessment for cognitive function of cancer survivors, although further data ...

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Sessions addressing supportive care needs for patients with cancer on early phase clinical trials appeared feasible and ...